Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Terveystalo, Q3'24

By Inderes10/25/2024, 7:30 AM
Terveystalo

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Katie Jackson
00:01 - 00:31

Good morning, everybody, and welcome to the Terveystalo Group Q3 results call and webcast. My name is Katie Jackson, and I'm responsible for investor relations and sustainability. As usual, we'll go through the results with the presentation by our CEO, Ville Iho, and our CFO, Juuso Pajunen. And we followed that with a Q&A. First, we'll take questions from the phone lines and then from the webcast as well. But without further ado, over to you, Ville.

Ville Iho
00:31 - 01:56

Thank you, Katie. So. Now I'm not able to change the slide. So, if. Okay. Now it works. So, the strong journey continues. The performance was again boosted, particularly by Healthcare Services, which is improving and continues to grow as a business as planned. We have seen encouraging signs in Portfolio Business, where profitability is improving amid fairly tough market conditions in both the public sector and consumer businesses. The Portfolio Business is running. Sweden is not yet showing bottom line results, but the turnaround is progressing and is expected to deliver results, as we have seen in Finland during the course of next spring. As you can see from the numbers, we will reach our financial targets in profitability one year ahead of the plan. And if you actually look at the LTM numbers, we have already crossed the line that we set early on. So, a 12% EBIT margin target.

Unknown 1
01:57 - 01:57

Uh.

Ville Iho
01:57 - 06:26

While we have, for the past 24 months, focused on profitability, we have maintained and even improved our customer satisfaction and medical quality, which is a very encouraging sign of a strong company, a strong culture, and robust operations. We have a gem. Okay. Now. So in numbers, Q3, we are growing by more than 5%. Uh, the EBITDA is 24.3 and the margin is 11.6%. Cash flow is strong as per usual. And also, EPS is showing almost a quantum leap forward. As said, customer satisfaction is at an all-time high again. So no matter how you slice and dice this slide, the performance is solid and still improving. Looking deeper into the businesses, Healthcare Services continues to deliver and perform. Continues to progress. Clear uptake in profitability and also in revenue for portfolio businesses. Revenue is going down due to the termination of outsourcing contracts and some headwinds in consumer businesses. But the important thing here is that we have been able to improve profitability with the actions that we are taking and will take in portfolio businesses, and we excel in that domain. We are getting ready for a healthcare district to open a new market opportunity for us. Sweden is still lagging behind, but as I said, a turnaround program has been initiated early in the year and is proceeding as planned, and will deliver results similar to what we have seen in Finland. Going forward. LTM figures here, as said, as a group, we have crossed a line that we set 24 months ago for the turnaround. So now we are in LTM figures. We are at 12.3%. EBITA well done by the team. Now. The group is strong. It's stronger than ever. And we concentrate on the next phase of the company, which is focusing more on growth, customer value, and medical quality. Medical quality storyline represented in the graph. This is the journey. So we set the targets for turnaround 24 months ago. We have been consistently delivering on the promises we have made. Delivering on performance improvement. The Alpha program is completed. The targets have been reached, and a new phase in the company will start. We have a lot of things that we can still improve. And now, since we are stronger than ever, we have the cash flow. We have the capacity to invest. We are, of course, glad to take the next step and next phase in the journey. We will invest in data superiority and prevention, ensuring ultimate smoothness and fluency in primary care and specialist care, and building world-class outpatient hospitals. A lot of things that we can still improve. The improvement has been material and it has been a great journey thus far. But there's still a lot of potential within the company, and the next phase of the journey will be discussed in detail in Helsinki. On the 4th of December at our Capital Markets Day, we will discuss that further. Over to you, user. Thank you, Will. Good morning.

Juuso Pajunen
06:26 - 17:26

Good morning to all. I'm extremely happy to be here today to present these numbers. Our Q3 is a strong one. It is the strongest Q3 in the company's history. If we exclude one Covid test supported quarter back in the day. So we are delivering and we are delivering at LTM 12.31, a year ahead of schedule. And it's not only that one, but if you look throughout all of our numbers, this is the sixth consecutive quarter that we've improved 62% up on EBITDA year on year. EPS four times net debt standing at 2.3, which is probably an all-time low for this group. So not only are we delivering adjusted EBITDA, delivering EPS, delivering cash flow, and seeing very strong NPS numbers, we also provide essentially effective medical care. We are not doing this at the cost of something. We are doing it because we are this good. If we then look at the numbers, the Finnish segments are clearly delivering healthcare services, both growing and improving margins materially. Portfolios are not showing growth in revenues but are improving the margin exactly as we have planned. Sweden's profit improvement program is on schedule, but we don't yet see the numbers going in the right direction. But if you analyze the numbers carefully, you can already see some very modest sequential improvement. And with all of this, the guidance range has been narrowed. Now, our full year guidance for adjusted EBITDA margin is between 12 and 12.5. So we have cut down the lower end of the margin range given in the summer. But let's go a bit more into the details. Revenue growth is driven by strong supply, improved sales mix, successful commercial actions, and an early flu season start. So we see clearly in the healthcare services, both appointments and diagnostics are delivering solid sales. Other service sales are slightly wobbling downwards, but there's nothing materially to worry about on that one. There is a bit of seasonality and then we have been renewing, for example, our operating theaters in camp, which has an impact on our operations. Obviously, then if we think a bit further about the growth, we are up in visits, roughly 3% up in visits. And at the same time, we had one additional working day. But even taking that one into account, we are still a couple of percentage points upwards, and the early start of the flu season contributes to that. But it's not the only explanation. We are also growing organically now at the appointment levels, which is very positive for our business. And then at the same time, it's not only appointments and diagnostics, it's true across all customer groups. So, positive performance from Healthcare Services when it comes to revenues in Portfolio Business. We can say that essentially, we have intentionally chosen to decline revenue in the public sector. Part of that involves Outsourcing, which we know very well. And at the same time, the staffing continues. The continuation of the storyline from the first six months that we have already detailed. So, we have deliberately chosen not to bid for everything. We want to keep our margin structure on a healthy base, and therefore, we have also implemented some revenue reduction. Consumer market. Dental massage continues to be at a lower level. Like I said earlier, it has probably bottomed out in February, but at the same time, we don't see any material improvement during the quarter. Demand remains low and continues at that level. Sweden. We have some terminated customer contracts, partly by choice and partly in the public sector. Tendering and the demand environment continue to be weak. There are some hints that it could get more positive, but at the same time it is a fragile environment from a demand perspective. But with all of this, we delivered €296 million in revenues in Q3 compared to €281 million the previous year. Then, if we go into the profitability aspect of Healthcare Services, we have implemented cost measures, established an efficiency program, and maintained a robust sales mix. But what is very important to understand is that we now have a far more balanced margin mix. So we are now, after all of the efficiency actions that we have taken, able to deliver solid margins throughout our different services, whether it's appointments, diagnostics, or operations and so on. We deliver margin and that essentially reduces the risk associated with our seasonality and supports our margin delivery. Then, the early flu season has a positive impact. It's roughly 2000 appointments per week from somewhere around mid-August onwards that we have gained compared to the previous year. Then, if we look at the portfolio of businesses, we see positive development, especially in the public sector, because we have been able to gain efficiencies. We had some loss-making old contracts that support us, or at least low margin contracts. And when those are out of the system, it supports the relative profitability. But it's not only that one; it's also growing in absolute terms. In Sweden, we are facing reduced revenue and cost inflation pressures. But once again, I reiterate we are progressing as planned in the profit improvement program. You are already beginning to see very modest hints on that part. If you think about it now, our Q3 revenues are declining a bit less than our year-to-date revenues. So now we are stabilizing out there. And at the same time, if you look at our number of people, if you look at the cost structure, we have taken some hard measures that are starting to be visible in the numbers. Step by step, we are moving forward. But having said that, Q4 will be difficult, and in 2025 we will be in a better position to make profits in Sweden. This picture you have seen, you will continue seeing it in the future. But what can I say? Story continued; thus, materially, nothing new in this one. In Healthcare Services, all customer groups or payer groups are growing in revenues. There is a hefty five percentage point improvement in margin. Also, portfolio businesses are almost doubling their margins. But the revenue is consistently going downwards. And Sweden, as explained, we are progressing in there, but it still takes further time year to year. To date, we have seen substantial improvement. Our big machine is ticking. And also here, I would like to highlight the consistency. We have been delivering these numbers now for six quarters in a row, and we have been progressing consistently quarter by quarter to reach this point. And now we are on 12.6. Year to date, adjusted EBITDA margins are at 12.3 over the last 12 months. Then if we think about the balance sheet side of things and our cash position, we are taking almost €200 million of operating cash flow during the quarter. This basically correlates with our operating margin improvement. The more we deliver EBITA, the more we deliver cash, and that operates like clockwork. Then, it's important to note that currently the gross CapEx stands at €37 million. On a 12-month basis, that is a low number. We have been repeatedly saying that it should be between 4 to 4.5 percentage points from the revenue, and at the same time, our eyes are turning more and more to organic growth, and that will require investments. So, we foresee that we have positive business cases to invest in organic growth. And potentially, the CapEx level will get higher in the future, but we will come back to that one also at the Capital Markets Day on December 4th. Net debt to adjusted EBITDA stands at 2.3. As I said, I think that it's at an all-time low during the history of this group, highlighting the cash generation, but also reminding all of us and all of you that we have the capability to invest if there are positive cases. Then, let's talk about the guidance. So basically, the first part of the guidance, as you know, is that we are expecting the revenues to grow. Now we have narrowed the range to 12 to 12.5. Then, if you look at the first five bullets, they are pretty much the same as they have been continuously, excluding the fifth bullet. Last statements. So now if you put this guidance into context, let's say that you would calculate the implied range for Q4 from here, year to date 12.6, ending up at 12 to 12.5 in a full year. You pretty much get into the mid-tens on the lower end and low twelves on the higher end of the guidance range. And that would indicate that Q4 would not be operationally great. But then you need to read the fifth bullet's final statements. We have some one-time items, not as adjustment items, but items that are now coming in the fourth quarter. We have the collateral labor agreement, where we have the one-time impact of €500 per employee that will be paid in December, and then we have a one-off payment to all staff that will be paid out in the fourth quarter, which will also affect the performance of the fourth quarter. Even with all of this in mind, it is fair to say the scenarios pointing to the upper end of the range seem to be more likely than any that would suggest the lower end of the range. So we are doing well also in Q4, but with these one-time items, I think it's time for Q&A and also a reminder about the commercial CMD on the 4th of December.

Katie Jackson
17:27 - 17:33

Excellent, thanks. I think that we are now ready for questions. Do we have any questions on the phone lines?

Operator
17:35 - 17:58

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Ansi Rousey from SEB. Please go ahead.

Unknown 2
18:00 - 18:22

Thank you, Andrea. Good morning, all. And firstly, congratulations again. Strong quarter. I start with the demand picture. And of course, there are many flu and influenza-type epidemics in Finland currently. But, how's the demand and the growth picture in early Q4? Like, do you see a clear impact here?

Juuso Pajunen
18:23 - 19:49

Well, to reiterate what I mentioned earlier, the flu season began around mid-August, and we have observed, give or take, 2000 more appointments per week for upper respiratory diseases. Through at least the first part of October, this trend has continued in the same manner, and you can very transparently follow this data on our Terveystalo Group website. Just search for Terveystalo Group data on Google, and you will be able to see that information very transparently. It has a couple of days' delay until it updates, but you get visibility on that one. Then, on the other part of the demand, we see continued positive trends. Like you see from our numbers, the corporate customers. We see insurance customers experiencing a positive development. Also, what about out-of-pocket customers and the public sector? I think that out-of-pocket customers, consumers, are still slightly feeling the effects of the now decreasing interest rates on their purchasing power. So that one is, I would say, more up-and-coming than the healthy development seen with the corporate customers, the insurance part, and finally the public sector. You know, the story we have chosen is indicative of our strategic direction in that sense. It has been declining throughout the year.

Unknown 2
19:52 - 20:11

Thanks. That's clear. And then you have been clear about your focus turning towards growth from now on. So can you perhaps provide us with some examples of the actions you are planning, or do we have to wait until the Capital Markets Day?

Ville Iho
20:12 - 21:03

So in a big picture, yes, you will need to wait a couple of weeks until the CMD. But one indication of our growth aspirations and initiatives was evident in users' comments about the investment. We have already started accelerating our growth with targeted investments in our portfolio. You will see that one in our numbers both in growth and in CapEx. That's one thing. Then, maybe the other significant aspect is that we have now reorganized the portfolio of businesses for public offering. Actually, yesterday we came out with the new brand. And we are really getting geared up for that market opening up in the future.

Katie Jackson
21:04 - 21:12

Yeah. Maybe just to elaborate, the focus remains on profitable and EPS-enhancing growth, of course, going forward as well.

Ville Iho
21:12 - 21:13

Absolutely.

Unknown 2
21:15 - 21:30

Thanks. And the last one, about your employees and the employee NPS. Uh, like, have you seen anything unusual in, let's say, employee churn, for example, or how has this developed?

Ville Iho
21:31 - 22:10

So regarding the attrition rate, we don't see any dramatic changes. There's, I would say, normal fluctuation there. The most important thing, which you mentioned already, is that supply has been developing positively all the time and continues to be very strong. Of course, this has been a fairly tough journey for our team during the last 24 months. And we, of course, want to give big thanks to the team for delivering and at the same time keeping customer satisfaction at a high level.

Unknown 2
22:12 - 22:15

Okay. Thank you. That's all from me.

Operator
22:18 - 22:24

The next question comes from Sammy Sarkoma from Danske Bank. Please go ahead.

Unknown 2
22:27 - 22:48

Hi. I have three questions. We'll take this one by one. Firstly, regarding your financial leverage, you were commenting that it's at an all-time low. Are you planning to keep it that way going forward? Or was this comment hinting at future acquisitions?

Juuso Pajunen
22:48 - 23:14

Well, I wouldn't take it as a hint. I would take it exactly as it states: an all-time low. So what it means is that we have the resources should we find positive growth investments, and we will address the capital allocation and investment questions at the Capital Markets Day. But as I said, we have the power to make positive organic growth investments or inorganic growth investments. Should we see opportunities emerging.

Unknown 2
23:16 - 23:36

Okay, then moving on to Sweden. I think you have previously indicated that we could see some early signs of recovery already in Q4. Now you're calling it a tough quarter. What is delaying the turnaround, and does a top-line turnaround require macroeconomic tailwinds?

Juuso Pajunen
23:36 - 24:31

Well, I think that covers two different topics. I think that both are true. It will be a tough quarter, but we will also see improvement. I think that we will continue to see sequential improvement. That is not an improvement against comparable numbers. So then we need to be clear on that part, but it will be a tough quarter. So it will be a tough quarter. But at the same time, I would expect that we will see some improvement on a month-on-month basis. So, that's the first part. Then the other part is that Sweden's macroeconomic environment is challenging. We would benefit from revenue growth and further increases in revenue. But our plan is built in a manner that accommodates even the lower end of revenues. We are capable of delivering satisfactory results. Not great results, but at least satisfactory results.

Unknown 2
24:33 - 24:47

Okay, thanks. And then finally, regarding the Finnish public sector as a customer seeking ongoing savings, are you anticipating growth from the public sector next year?

Ville Iho
24:48 - 25:35

Well, it's very difficult to estimate that one because it's a factor for any healthcare district. It's like a binary situation for many areas. However, there are some signs that the activities are actually materializing. The Pirkanmaa decision, for example, just a couple of days ago was one indication that things are moving. But we are not yet forecasting anything. We are getting ready and geared up, as I said, for ultimate eventual growth that will emerge and the market will open up. But it's as we have discussed earlier, very difficult to forecast.

Unknown 2
25:37 - 25:39

Okay. Thank you. I don't have any further questions.

Operator
25:44 - 25:49

The next question comes from Johnny Sandoval from Nordia. Please go ahead.

Unknown 2
25:50 - 26:17

Yeah. Thanks, Ville Iho and Juuso Pajunen, and congrats for the good results. I have a couple of questions. Firstly, on personal expenses. This decline is clear year over year. So were there any extraordinary reasons behind the decline. And secondly, have you seen any increase in sickness leave due to the flu season? And how should we expect this to compare now against last year? In Q4?

Juuso Pajunen
26:18 - 27:14

First of all, the personnel expenses last year included the CLA additional payment, which was made in the third quarter, if I recall correctly. So that one means that there was an excess impact of, I'd say, a couple of million euros in the comparable numbers from the previous year. And then on the sickness leaves, we see some small growth. So we are not living in a bubble as a company, isolated from the surrounding environment. So the extended flu season exhibits a slight impact on sickness leaves, but there is nothing material at the moment. And I think that we have been quite effective during the profit improvement program in improving our rostering. So we are quite well prepared for a kind of normal. Normal volatility that sicknesses may cause.

Unknown 2
27:16 - 27:39

Okay. Thanks. And then maybe a question on organic growth going into 2025. I know that you will give more information at the Capital Markets Day. But how does it look now, considering pricing and volumes, taking into account the current inflation environment? What kind of underlying growth in the market should we expect?

Juuso Pajunen
27:40 - 28:40

Well, at the moment I would not like to comment too much on the 2025 growth environment. We believe the market environment is stable from most macro perspectives. There are open components, obviously, that if we see a more favorable macroeconomic environment, it should probably be visible in our consumer-driven demand, especially. And of course, the employment rates could potentially start increasing in Finland with those funds. But this is all guessing. But I would say that from an organic growth perspective, we have solid and good visibility for 2025. Or we would expect to see pricing that supports organic growth. Obviously, we are living in our times. We have been living in a high inflation environment for the past couple of years. We have been living in a high inflation environment, and now we are coming into a stable inflation environment. And of course, that will also have an impact on our pricing.

Unknown 2
28:42 - 29:11

Okay. Okay. Thanks. Lastly, regarding the changes in reimbursements, I think there have been proposals to shift towards more selective care. How do you see these proposals, and could this actually be more supportive to you than the current change? What happened earlier this year?

Ville Iho
29:13 - 31:24

The starting point is that the proposal currently on the table is smarter than the previous one for many different aspects. First of all, it's a phased approach which is very important for this type of complicated systems. Also, as you progress in phases, the focus is more pronounced. So basically, reimbursements are focused in areas which are perhaps the most congested, and where the private sector can most effectively assist the public sector. So, those are welcomed changes to the proposal. Then the trial or pilot for citizens over 65 is a good pick. I think it's a very viable idea, typically in that segment, people fall off from occupational healthcare. And there's a segment that we can serve with our private offering. So many positive things in the proposal. Of course, then when you scratch the surface, the questions about how you develop this system into a freedom of choice type of model, which is the background for the pilot, arise. Then you encounter numerous questions regarding pricing mechanisms, etc. etc. But we are very supportive and glad to see this type of thinking initially happening and this type of proposal being put on the table. Um, one caveat though is that since we are moving ahead in phases, any material impact would take time. So this is hopefully the beginning of something new where we can serve new segments with our private offering, a new opening for the freedom of choice model. But it will take time to materialize.

Unknown 2
31:25 - 31:29

Okay, thanks. Good. Good answer. That's all from me. Thanks.

Operator
31:32 - 31:39

There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Katie Jackson
31:41 - 32:04

Thank you. Operator. At the moment, we don't have any questions from the chat. So as a reminder, if you're watching and have questions, do send them over. Maybe just a couple of words going back to the results. Um, now we are turning our focus from the turnaround to a new phase. Any teasers before our Capital Markets Day? What does it mean in practice?

Ville Iho
32:05 - 32:49

So, we as a company have had many things to fix within our operations over the past 24 months. This has been, for that reason, although the results have been great, a very internally focused company, for good reasons. Now, the job on that front is done. We will turn our focus to the external world, to the markets, to the customers, to the patients, and to the quality of organic growth. And that's the key for the next phase. But, we'll discuss that one in detail during our Capital Markets Day.

Katie Jackson
32:50 - 32:58

Excellent. We don't have any questions from the audience at the moment. So. So, we thank you for your time and hope you have a great weekend.

Ville Iho
32:58 - 33:00

Thank you, thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…